Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 19/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590069 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL1807930 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9048729 | 0.94 | ALOX5 (0.88) | ALOX5EPHX2 | |
| SCHEMBL12420450 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL13140099 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL9047929 | 0.90 | ALOX5 (0.81) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047669 | 0.90 | ALOX5 (0.81) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9049110 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9049256 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047887 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998058644-A1 | (S)-(-)-N-[3- [5-(4-FLUOROPHENOXY) -2-FURANYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| CN-1652822-A | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | ALTANA PHARMA AG (DE) | 2005-08-10 | — | — | CN | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-1998058644-A1 | (S)-(-)-N-[3- [5-(4-FLUOROPHENOXY) -2-FURANYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| US-5591451-A | SUSTAINED RELEASE; STABILITY | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1995005808-A1 | OIL-BASED TABLETING METHOD | ABBOTT LABORATORIES (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | ALOX5 700/4885EPHX2 134/4885ACACB 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.